English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduValue in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced the publication of a report that identifies expensive Medicare Part B drugs with low added therapeutic benefit and models a reimbursement policy for them based on domestic reference pricing.
Tag: drug pricing
New Research Addresses the Drug Pricing Conundrum: Encouraging Innovation While Maintaining Affordability
Value in Health, the official journal of ISPOR, announced the publication of a series of articles describing important new research related to drug pricing globally. The articles were published in the March 2023 issue of the journal.
Researchers find medical industry funded studies more likely to find new treatments cost effective
New drugs and technologies covered by insurance plans can be much more profitable than those not covered, which may lead to bias in CEAs funded by pharmaceutical or other medical industry firms.
The research team gleaned its data by analysing the results of more than 8,000 CEAs published between 1976 and March 2021. Nearly 30 per cent of these CEAs were sponsored by industry.
Endocrine Society celebrates House passage of Build Back Better Act
The Endocrine Society hailed the House of Representatives for including provisions to improve insulin affordability in its version of the Build Back Better Act.
Biden focuses on health care, but pharma firms have upper hand
President-elect Joe Biden began transition planning with the announcement of a COVID-19 task force, continuing a focus on health care that was a hallmark of the Obama-Biden era, culminating in the passing of the Affordable Care Act. Colleen Carey,…
Offering a Pay-for-Performance Program to Oncology Practices Increases Prescriptions of Evidence-based Cancer Drugs
A pay-for performance program that offers enhanced reimbursement to oncology practices for prescribing high-quality, evidence-based cancer drugs increased use of these drugs without significantly changing total spending on care, Penn Medicine researchers report in a new study published online in the Journal of Clinical Oncology.
ISPOR Top 10 HEOR Trends Webinar Announced
ISPOR—The Professional Society for Health Economics and Outcomes Research (HEOR) announced a new webinar on its ISPOR 2020 Top 10 HEOR Trends report. The free webinar will be held Thursday, March 26, 2020 at 11:00AM EDT and is available for both members and nonmembers.
ISPOR Publishes 2020 Top 10 Health Economics and Outcomes Research (HEOR) Trends Report
ISPOR—the professional society for health economics and outcomes research (HEOR), announced the publication of its 2020 Top 10 HEOR Trends report. In the report, the Society has identified the top 10 HEOR trends that will shape the field and influence healthcare over 2020 and the near future.